Evidence map›Paper›PMID 39766343›Full record

ArticleBiomolecules2024

Celecoxib Combined with Tocilizumab Has Anti-Inflammatory Effects and Promotes the Recovery of Damaged Cartilage via the Nrf2/HO-1 Pathway In Vitro.

Miyako Shimasaki, Shusuke Ueda, Masaru Sakurai, Norio Kawahara, Yoshimichi Ueda, Toru Ichiseki

Abstract read
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miyako ShimasakiDepartment of Pathology 2, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan.
Shusuke UedaDepartment of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan.ORCID 0000-0003-3385-032X
Masaru SakuraiSocial and Environmental Medicine, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan.
Norio KawaharaDepartment of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan.
Yoshimichi UedaDepartment of Pathology, Keiju Medical Center, 94, Tomioka-machi, Nanao 926-0816, Japan.
Toru IchisekiDepartment of Orthopaedic Surgery, Kanazawa Medical University, Daigaku 1-1, Uchinada-machi, Kahoku-gun 920-0293, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation and oxidative stress are crucial for osteoarthritis (OA) pathogenesis. Despite the potential of pharmacological pretreatment of chondrocytes in preventing OA, its efficacy in preventing the progression of cartilage damage and promoting its recovery has not been examined. In this study, an H

Indexed as

Antibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsCelecoxibChondrocytesNF-E2-Related Factor 2OsteoarthritisSignal TransductionCartilage, ArticularCell LineCyclooxygenase 2Heme Oxygenase-1HumansHydrogen PeroxideInterleukin-6Matrix Metalloproteinase 13Oxidative StressAntibodies, Monoclonal, HumanizedAnti-Inflammatory AgentsCelecoxibCyclooxygenase 2Heme Oxygenase-1HMOX1 protein, humanHydrogen PeroxideInterleukin-6Matrix Metalloproteinase 13NFE2L2 protein, humanNF-E2-Related Factor 2tocilizumabantioxidantcartilage damagecelecoxibchondrocytesheme oxygenase-1Nrf2oxidative stresstocilizumab

Identifiers

PMID39766343
PMCPMC11727524

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.